Exploring Research on Alzheimer’s Disease and other Types of Dementia
Welcome to Minding Memory. In this podcast we discuss topics related to dementia research. This is an all-hands-on-deck moment for dementia research, and we have topics for both those new to the space as well as old pros. We start with some basics, like: What exactly is dementia? What are the different types of dementia? What is the TICS, if not a swarm of blood-sucking insects? But we also invite researchers on to discuss their interesting work to give you a glimpse at the questions, data, and methods moving the field forward.
Minding Memory is co-hosted by Matthew Davis and Donovan Maust. Matt and Donovan are Associate Professors and health services researchers at the University of Michigan. Matt’s PhD is in data science and Donovan is a psychiatrist. The Minding Memory podcast is part of the Center to Accelerate Population Research in Alzheimer’s (CAPRA) at the University of Michigan, supported by the National Institute on Aging at the National Institutes of Health. Additional support also comes from the Institute for Healthcare Policy and Innovation. The content of this podcast does not represent the views of the National Institutes of Health or the University of Michigan. Please consider subscribing to this podcast and make sure to check out our website at: https://capra.med.umich.edu/. On our website you’ll also find links to the center’s seminar series and data products created specifically for dementia research.
October 11, 2021
Introduction to the Minding Memory Podcast
In this episode we introduce ourselves and provide an overview of the Minding Memory Podcast. This podcast is supported by the Center to Accelerate Population Research in Alzheimer’s (CAPRA) at the University of Michigan. Our guest this week is Dr. Julie Bynum. Julie is the director of CAPRA and we talk briefly about what the NIH-funded research center is and how to get involved.
Available October 25, 2021
What is the Value of Early Detection of Dementia?
In this episode we talk with Dr. Ken Langa about the implications of identification of “preclinical” Alzheimer’s disease (situations where individuals may have biological signs of Alzheimer’s but no symptoms). Ken is a leading dementia researcher and our discussion focuses on an article he published called “Preclinical Alzheimer Disease – Early Diagnosis or Overdiagnosis” that was published in JAMA Internal Medicine. In his article co-authored with Dr. Jim Burke, he brings up some of the potential indirect effects of early detection.
Available November 8, 2021
Could the FDA’s Approval of a New Drug to Treat Alzheimer’s Disease do More Harm than Good?
Aducanumab is a new drug designed to remove amyloid in the brain. Following an accelerated process, the Food and Drug Administration approved Aducanumab as a treatment for Alzheimer’s disease despite (what many experts feel) little evidence of effectiveness. In this episode we discuss the approval of Aducanumab with Dr. Jason Karlawish from the University of Pennsylvania and talk about what it could mean for drug discovery going forward.
Available November 22, 2021
What are the Implications of the Approval of Aducanumab to the US Healthcare System?
In this episode we continue our discussion of the implications of the approval of Aducanumab. Our guest this week is Dr. Nicholas Bagley. Dr. Bagley is a professor of law at the University of Michigan Law School and a contributing writer to the Atlantic. Recently he wrote an article titled “The Drug that Could Break American Health Care” that discusses some of the broader (unintended) consequences of the approval of Aducanumab. In this episode we discuss some of the broader cost implications of the new drug.
Available December 6, 2021
What are the Different Types of Dementia? A Primer for those of us who aren’t Healthcare Clinicians
Often research studies consider dementia as either present or absent, while others specify particular types of dementia. For example, what exactly is frontotemporal dementia? In this episode, we talk with Dr. Henry (Hank) Paulson, who directs the Michigan Alzheimer’s Disease Center, to introduce listeners to the most common types of dementia and hear about some of their defining features. For those of you without clinical backgrounds, consider this your crash course on the types of dementia.
Available December 20, 2021
Keep it Down out There: You’re Hurting my Brain
Our guest in this episode is Dr. Sara Adar. She is an associate professor at the University of Michigan School of Public Health in the department of epidemiology. Dr. Adar was the senior author on a study titled “Long-term community noise exposure in relation to dementia, cognition, and cognitive decline in older adults” that was published in the journal Alzheimer’s & Dementia. The study used data from the Chicago Health and Aging Project to examine the association between exposure to community noise and cognitive impairment. We talk with her about how exposure to noise affects cognition.
Available January 3, 2022
Drugs and Dementia: The Good, the Bad, and the Ugly
While there are some FDA-approved medications for dementia, more individuals living with dementia are actually prescribed psychotropic medications. In this episode, Donovan introduces Matt to the concept of the behavioral and psychological symptoms of dementia, which are just as much part of dementia as the memory loss—and are probably a big reason for all this other prescribing.
Available Janury 17, 2021
Donovan Takes the Telephone Interview for Cognitive Status
One of the richest data sources available to study cognition and aging is the Health and Retirement Study (HRS). This nationally representative survey includes questions to help assess cognition, but many researchers may use this data without actually knowing the questions behind the variables—don’t be That Guy! (or Gal!) Listen to a HRS team member coach Matt as he administers the Telephone Interview for Cognitive Status (TICS) to Donovan, who is surprisingly good at recalling types of birds.